Jonathan Webster, MD

Jonathan Webster, MD, and Nikesh Shah, MD, discuss ALL data and research to look out for at ASH 2025.

Ongoing research explores the logistics and efficacy of blinatumomab, aiming to enhance patient access and treatment outcomes in leukemia therapy.

Jonathan Webster, MD, and Nikesh Shah, MD, discuss data for blinatumomab in younger adult patients with BCR:ABL1–negative B-ALL.

Jonathan Webster, MD, and Nikesh Shah, MD, discuss who age and Philadelphia chromosome status influence blinatumomab initiation in ALL.

Jonathan Webster, MD, and Nikesh Shah, MD, explore the current role of blinatumomab in acute lymphoblastic leukemia management.

Jonathan Webster, MD, and Nikesh Shah, MD, detail current treatment approaches in frontline acute lymphoblastic leukemia.